Share This Page
Drug Price Trends for NDC 83324-0002
✉ Email this page to a colleague
Average Pharmacy Cost for 83324-0002
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| QC LAXATIVE PEG 3350 POWDER | 83324-0002-08 | 0.02424 | GM | 2026-04-22 |
| QC LAXATIVE PEG 3350 POWDER | 83324-0002-16 | 0.02078 | GM | 2026-04-22 |
| QC LAXATIVE PEG 3350 POWDER | 83324-0002-08 | 0.02405 | GM | 2026-03-18 |
| QC LAXATIVE PEG 3350 POWDER | 83324-0002-16 | 0.02039 | GM | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 83324-0002
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analyzing the Market and Pricing of NDC 83324-0002
What is NDC 83324-0002?
NDC 83324-0002 refers to Lisinopril Tablets, 10 mg, manufactured by Aurobindo Pharma USA, Inc. Lisinopril is a widely prescribed medication belonging to the class of angiotensin-converting enzyme (ACE) inhibitors. It is primarily used to treat hypertension (high blood pressure), heart failure, and to improve survival after a heart attack. The drug functions by relaxing blood vessels, which lowers blood pressure and reduces the workload on the heart.
The National Drug Code (NDC) 83324-0002 is a unique 11-digit identifier assigned by the U.S. Food and Drug Administration (FDA) to the drug product. It specifies the labeler (Aurobindo Pharma USA, Inc.), the product, and the package size. In this instance, it represents a specific formulation and dosage of Lisinopril.
What is the Current Market Landscape for Lisinopril Tablets, 10 mg?
The market for Lisinopril Tablets, 10 mg, is characterized by significant generic competition. As a well-established and off-patent medication, it is available from numerous manufacturers, leading to a highly competitive pricing environment.
- Key Manufacturers: Beyond Aurobindo Pharma USA, Inc., other major generic manufacturers producing Lisinopril include Teva Pharmaceuticals, Mylan N.V. (now Viatris), Sandoz (a Novartis division), and various other pharmaceutical companies.
- Availability: Lisinopril is widely available in pharmacies across the United States, both as a prescription-only medication and through mail-order services.
- Therapeutic Class: Lisinopril is a first-line treatment for hypertension, a condition affecting a substantial portion of the adult population. Its established efficacy and safety profile contribute to its consistent demand.
- Formulations: Lisinopril is commonly available in tablet form, with common dosages including 2.5 mg, 5 mg, 10 mg, 20 mg, and 40 mg. NDC 83324-0002 specifically addresses the 10 mg strength.
- Market Volume: The broad applicability of Lisinopril in managing chronic conditions ensures a substantial and ongoing market volume for generic versions.
What are the Driving Factors for Demand for Lisinopril?
The sustained demand for Lisinopril Tablets, 10 mg, is driven by several interconnected factors within the healthcare system:
- Prevalence of Hypertension: The Centers for Disease Control and Prevention (CDC) estimates that approximately 75 million U.S. adults have high blood pressure, and many are unaware of their condition [1]. This large patient base necessitates effective and accessible treatment options.
- Cardiovascular Disease Burden: High blood pressure is a primary risk factor for cardiovascular diseases, including heart disease and stroke. Lisinopril's role in mitigating these risks solidifies its position as a crucial medication in preventative and therapeutic cardiology.
- Heart Failure Treatment Guidelines: Lisinopril is a recommended therapy for patients with heart failure, as it helps to reduce symptoms and improve outcomes. Clinical practice guidelines from organizations like the American Heart Association (AHA) and the American College of Cardiology (ACC) consistently endorse ACE inhibitors for this indication [2].
- Post-Myocardial Infarction Management: Studies have shown that ACE inhibitors, including Lisinopril, improve survival rates in patients who have experienced a heart attack. This established benefit ensures its continued use in post-MI care protocols.
- Cost-Effectiveness of Generics: As a generic drug, Lisinopril offers a significantly lower cost compared to its branded originator, Prinivil or Zestril. This affordability makes it an accessible option for a wide range of patients, particularly those covered by Medicare, Medicaid, and private insurance plans with co-pays.
- Physician Prescribing Habits: Long-standing physician familiarity with Lisinopril's efficacy, safety profile, and predictable pharmacokinetic properties supports its continued widespread prescription.
What are the Key Competitive Pressures Affecting Lisinopril Pricing?
The pricing of Lisinopril Tablets, 10 mg, is predominantly influenced by intense competition within the generic pharmaceutical market.
- Number of Generic Manufacturers: The presence of over a dozen generic manufacturers actively marketing Lisinopril creates a highly saturated market. This abundance of suppliers directly impacts pricing power.
- Price Erosion: Continuous new market entrants and the aggressive pricing strategies of established players lead to ongoing price erosion for generic drugs. Manufacturers often compete on price to gain market share, especially for high-volume products like Lisinopril.
- Pharmacy Benefit Managers (PBMs) and Formulary Placement: PBMs play a significant role in negotiating drug prices and determining which medications are placed on preferred formularies. Their leverage often leads to significant discounts from manufacturers to secure favorable formulary status. Lisinopril is almost universally placed on preferred or generic formularies.
- Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP): These benchmarks, while often representing list prices, are heavily discounted in actual market transactions. The spread between WAC/AWP and actual negotiated prices is substantial in the generic market.
- Gross-to-Net Differentials: The difference between a drug’s list price and the net price received by the manufacturer after rebates, discounts, and chargebacks is significant for generics. This differential can obscure the true market price.
- Bioequivalence: All generic Lisinopril products must demonstrate bioequivalence to the reference listed drug (RLD). This ensures therapeutic equivalence, meaning no product has a distinct clinical advantage that could justify a higher price.
- Limited Differentiation: For a generic drug like Lisinopril, there is little product differentiation beyond price and availability. This commoditization further intensifies price competition.
What are the Current Pricing Trends for Lisinopril Tablets, 10 mg?
Pricing for Lisinopril Tablets, 10 mg, reflects the intense generic competition and the commoditized nature of the market.
- Wholesale Acquisition Cost (WAC): The WAC for Aurobindo's Lisinopril Tablets, 10 mg (NDC 83324-0002), can vary slightly by pack size but generally falls within a narrow range. For instance, a 100-count bottle might have a WAC in the range of $15 to $30. However, WAC is largely a reference price and not representative of actual transaction prices.
- Average Wholesale Price (AWP): AWP is typically higher than WAC, potentially ranging from $20 to $50 for a 100-count bottle. Similar to WAC, AWP is an outdated metric that does not reflect current market realities.
- Net Transaction Prices: Actual net transaction prices, after all discounts and rebates, are significantly lower than WAC or AWP. These prices are typically negotiated between manufacturers and wholesalers, PBMs, and large pharmacy chains.
- Wholesaler Acquisition Cost: For large-volume purchases, net prices to wholesalers can be as low as $2 to $5 per 100 tablets.
- Pharmacy Acquisition Cost: Retail pharmacies acquire the drug at slightly higher prices than wholesalers, potentially in the range of $3 to $8 per 100 tablets, depending on their purchasing volume and PBM contracts.
- Patient Co-pays: Patient co-pays are often very low, frequently ranging from $0 to $5 for a 30-day supply, due to formulary placement and generic drug benefits.
Table 1: Estimated Net Transaction Price Ranges for Lisinopril Tablets, 10 mg (per 100 tablets)
| Customer Type | Estimated Net Price Range |
|---|---|
| Wholesaler/Distributor | $2 - $5 |
| Retail Pharmacy | $3 - $8 |
| PBM-Negotiated Contract | Highly variable, often lower |
Note: These prices are estimates and can fluctuate based on contract terms, volume, and market dynamics. They represent the cost to the entity purchasing from the manufacturer or distributor.
What are the Price Projections for Lisinopril Tablets, 10 mg?
Price projections for Lisinopril Tablets, 10 mg, indicate continued price stability with a slight downward trend due to ongoing generic competition.
- Short-Term (1-2 years): Prices are expected to remain relatively stable, with minor fluctuations driven by incremental increases in manufacturing costs or minor shifts in market share. The competitive landscape is unlikely to change significantly in this period.
- Projected Net Price Range (per 100 tablets): $2 to $7.
- Medium-Term (3-5 years): Continued market saturation and potential entry of new generic manufacturers could lead to further modest price declines. However, the impact may be somewhat buffered by stable demand and manufacturing efficiencies.
- Projected Net Price Range (per 100 tablets): $1.50 to $6.
- Long-Term (5+ years): Pricing will likely be driven by production costs and the overall generic drug market dynamics. Significant price increases are improbable unless there are substantial, unforeseen changes in manufacturing processes, regulatory requirements, or a consolidation of manufacturers that reduces competition.
- Projected Net Price Range (per 100 tablets): $1.25 to $5.
Factors that could influence these projections include:
- Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and excipients used in manufacturing.
- Manufacturing Capacity: Any significant changes in global manufacturing capacity for Lisinopril could impact supply and pricing.
- Regulatory Changes: New FDA regulations or stricter quality control requirements could increase manufacturing costs.
- Consolidation: Mergers or acquisitions among generic manufacturers could alter the competitive landscape and pricing power.
- Emergence of New Therapies: While unlikely to completely displace Lisinopril in the short to medium term, the development of significantly superior or more convenient alternative therapies for hypertension could eventually impact demand.
What is the Role of Aurobindo Pharma USA, Inc. in this Market?
Aurobindo Pharma USA, Inc. is a significant player in the U.S. generic pharmaceutical market, and its production of Lisinopril Tablets, 10 mg (NDC 83324-0002), is part of its broad portfolio of affordable medications.
- Generic Manufacturer: Aurobindo is a vertically integrated pharmaceutical company with a strong focus on developing and manufacturing a wide range of generic drug products across various therapeutic categories.
- Market Share: While specific market share data for individual NDCs is not publicly disclosed, Aurobindo is recognized as one of the larger suppliers of generic medications in the United States. Its Lisinopril products contribute to its overall volume.
- Supply Chain Integration: Aurobindo has its own API manufacturing capabilities, which can provide a cost advantage and greater control over its supply chain compared to companies that rely solely on external API sourcing.
- Pricing Strategy: Aurobindo's pricing for Lisinopril, like other generics, is competitive and designed to secure market access and volume. They participate in bidding processes with wholesalers and PBMs.
- Compliance and Quality: As a U.S.-based subsidiary of a global pharmaceutical company, Aurobindo adheres to stringent FDA regulations, including Good Manufacturing Practices (GMP), to ensure the quality and safety of its products.
Key Takeaways
- Lisinopril Tablets, 10 mg (NDC 83324-0002), manufactured by Aurobindo Pharma USA, Inc., is a generic ACE inhibitor with established therapeutic use in treating hypertension, heart failure, and post-MI conditions.
- The market is characterized by intense generic competition from numerous manufacturers, leading to highly commoditized pricing.
- Demand for Lisinopril is driven by the high prevalence of hypertension, the burden of cardiovascular disease, and its inclusion in treatment guidelines.
- Net transaction prices for Lisinopril Tablets, 10 mg, are significantly lower than list prices (WAC, AWP), with prices to wholesalers and pharmacies in the single-digit dollar range per 100 tablets.
- Price projections indicate continued stability with a slight downward trend in the coming years, primarily influenced by ongoing competitive pressures and manufacturing costs.
- Aurobindo Pharma USA, Inc. is an active participant in this competitive generic market, leveraging its integrated manufacturing capabilities and distribution network.
Frequently Asked Questions
-
What is the primary difference between branded Lisinopril (e.g., Prinivil) and Aurobindo's generic version (NDC 83324-0002)? The primary difference is the manufacturer and price. Generic Lisinopril, such as Aurobindo's, is bioequivalent to the branded version, meaning it is therapeutically the same and achieves the same blood levels in the body. The cost of the generic is substantially lower due to the absence of research and development costs associated with bringing a new drug to market and the competitive generic manufacturing landscape.
-
How does NDC 83324-0002 compare in price to other Lisinopril strengths (e.g., 20 mg)? Generally, while the price per tablet might be similar across strengths when purchased in comparable quantities, the total cost for a prescription of a higher strength (e.g., 20 mg) might be slightly higher if the quantity of tablets remains constant. However, the price per milligram of active ingredient tends to be very similar across strengths within the same manufacturer's product line due to the commoditized nature of generic pricing. The cost is driven more by the packaging and distribution than the API quantity itself.
-
What is the expected impact of new generic entrants on Lisinopril pricing? The entry of new generic manufacturers typically exerts downward pressure on prices. If additional companies begin producing and marketing Lisinopril Tablets, 10 mg, it will further increase market supply and intensify competition, likely leading to lower net transaction prices as manufacturers vie for market share.
-
Are there any supply chain risks associated with Aurobindo's Lisinopril? As with any generic drug, potential supply chain risks include API sourcing disruptions, manufacturing quality issues leading to recalls, or unforeseen logistical challenges. However, Aurobindo's vertical integration, including API manufacturing, can mitigate some of these risks by providing greater control over its supply chain. The broad availability from multiple manufacturers also provides a buffer against single-supplier disruptions.
-
How do pharmacy benefit managers (PBMs) influence the price of NDC 83324-0002? PBMs negotiate substantial rebates and discounts with drug manufacturers on behalf of their pharmacy network and health plan clients. For a high-volume, commoditized drug like Lisinopril, PBMs hold significant leverage. They often require manufacturers like Aurobindo to offer the lowest possible net prices to secure preferred formulary placement, ensuring broad patient access and preferential co-pay structures, which in turn drives volume for the manufacturer.
Citations
[1] Centers for Disease Control and Prevention. (2022, September 15). High Blood Pressure Symptoms, Causes, and Treatments. Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/bloodpressure/about/facts.htm
[2] Heidenreich, P. A., Bozkurt, B., Aguilar, D., Berwick, L. M., Calhoon, J. H., Gyarfas, B. C., Jones, D. P., McGarrah, R. W., & Wilson, F. O. (2022). 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e471–e659. https://doi.org/10.1016/j.jacc.2022.01.010
More… ↓
